Cytiva, a provider of technologies and services in the therapeutics industry, has bought Cevec Pharmaceuticals, a German-based cell line developer and viral vector manufacturer.

According to Cytiva, one of the pharmaceutical industry’s biggest challenges in cell and gene therapy is establishing product processes that can keep up with the demand for volume and consistent quality of viral vectors. Cevec covers two vectors for delivering therapeutic genes to target cells and tissues with its cell lines based on Adeno-Associated Virus and Adenovirus. The acquisition aims to strengthen Cytiva’s position in biomanufacturing services. Cevec and its team will join Cytiva immediately.

“Cevec’s innovative technology complements Cytiva’s offering and brings the promise of improved viral vector manufacturing,” says Emmanuel Abate, genomic medicine at Cytiva. “With Cytiva’s global reach and ability to scale, more customers will have access to Cevec’s technology and expertise to help accelerate and advance therapeutics for the benefit of patients.”

William Blair served as financial adviser to Cevec Pharmaceuticals in this transaction.